NOTRE PIPELINE

Nous tirons parti de notre plateforme exclusive SNIPRx pour découvrir, valider et construire un pipeline clinique et préclinique solide de thérapies oncologiques à base de LS.

Notre Pipeline

Programme
Lésion tumorale
  • Découverte
  • IND-Enabling
  • Ph 1/2
  • Pivotal
Rights

Camonsertib
ATR Inhibitor

ATM + 16 additional lesions
  • Disc.
  • Ph 1/2
  • Ph 1/2
TRESR: Monotherapy
  • Ph 1/2
TRESR: PARP (talazoparib) Combo
repare logo small

Lunresertib
PKMYT1 Inhibitor

CCNE1,
FBXW7 + others
  • Ph 1/2
CCTG ISTs
  • Ph 1/2
MYTHIC: Monotherapy
  • Ph 1/2
MAGNETIC: Gemcitabine Combo
repare logo small

RP-1664
Undisclosed

Undisclosed
  • IND.
repare logo small

Discovery Program
Multiple Targets

Undisclosed
  • Disc.
repare logo small

Discovery Program
Multiple Targets

Undisclosed
  • Disc.
repare logo small
Cibles
ATR Inhibitor
Lésion tumorale
ATM + 16 additional lesions
Progrès
Phase 1/2
Essais Cliniques
TRESR: Monotherapy
Progrès
Phase 1/2
Essais Cliniques
TRESR: PARP (talazoparib) Combo
Progrès
Phase 1/2
Droits
Roche
Repare
Cibles
PKMYT1 Inhibitor
Lésion tumorale
CCNE1,
FBXW7 + others
Essais Cliniques
CCTG ISTs
Progrès
Phase 1/2
Essais Cliniques
MYTHIC: Monotherapy
Progrès
Phase 1/2
Essais Cliniques
MAGNETIC: Gemcitabine Combo
Progrès
Phase 1/2
Droits
Repare
Cibles
Undisclosed
Lésion tumorale
Undisclosed
Progrès
IND. Enabling
Droits
Repare
Cibles
Multiple Targets
Lésion tumorale
Undisclosed
Progrès
Discovery
Droits
Repare
Cibles
Multiple Targets
Lésion tumorale
Undisclosed
Progrès
Discovery
Droits
Bristol Myers Squibb

Découvrez notre collection de programmes d’essais cliniques en cours.